Published in J Clin Gastroenterol on October 15, 2010
Diversity of the human intestinal microbial flora. Science (2005) 49.64
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Risk of developing colorectal cancer following a negative colonoscopy examination: evidence for a 10-year interval between colonoscopies. JAMA (2006) 6.26
How many duodenal biopsy specimens are required to make a diagnosis of celiac disease? Gastrointest Endosc (2008) 4.58
Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med (2004) 4.10
A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology (2005) 4.06
The reduction in colorectal cancer mortality after colonoscopy varies by site of the cancer. Gastroenterology (2010) 3.87
Association between the use of antibiotics in the first year of life and pediatric inflammatory bowel disease. Am J Gastroenterol (2010) 3.12
Rate and predictors of early/missed colorectal cancers after colonoscopy in Manitoba: a population-based study. Am J Gastroenterol (2010) 2.97
Tolerability of malaria chemoprophylaxis in non-immune travellers to sub-Saharan Africa: multicentre, randomised, double blind, four arm study. BMJ (2003) 2.87
Work losses related to inflammatory bowel disease in Canada: results from a National Population Health Survey. Am J Gastroenterol (2003) 2.63
Frequency of colorectal cancer screening and the impact of family physicians on screening behaviour. CMAJ (2007) 2.60
Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol (2007) 2.46
Knowledge, attitudes and practices in travel-related infectious diseases: the European airport survey. J Travel Med (2004) 2.44
High prevalence of Escherichia coli belonging to the B2+D phylogenetic group in inflammatory bowel disease. Gut (2006) 2.43
Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol (2009) 2.36
Association between the use of antibiotics and new diagnoses of Crohn's disease and ulcerative colitis. Am J Gastroenterol (2011) 2.32
Information needs and preferences of recently diagnosed patients with inflammatory bowel disease. Inflamm Bowel Dis (2011) 2.31
Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am J Gastroenterol (2009) 2.22
Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology (2011) 2.22
Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm Bowel Dis (2009) 2.15
Do NSAIDs, antibiotics, infections, or stress trigger flares in IBD? Am J Gastroenterol (2009) 2.05
Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol (2008) 1.92
AGA technical review on osteoporosis in hepatic disorders. Gastroenterology (2003) 1.89
Emergence of medicine for mass gatherings: lessons from the Hajj. Lancet Infect Dis (2012) 1.89
Geographical variability and environmental risk factors in inflammatory bowel disease. Gut (2013) 1.84
Long-term use of statins and risk of colorectal cancer: a population-based study. Am J Gastroenterol (2009) 1.83
World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis (2010) 1.82
Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol (2003) 1.80
Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 1.73
The Manitoba IBD cohort study: a population-based study of the prevalence of lifetime and 12-month anxiety and mood disorders. Am J Gastroenterol (2008) 1.72
Prevalence of enteric pathogens among international travelers with diarrhea acquired in Kenya (Mombasa), India (Goa), or Jamaica (Montego Bay). J Infect Dis (2002) 1.64
Microbial diversity of inflamed and noninflamed gut biopsy tissues in inflammatory bowel disease. Inflamm Bowel Dis (2007) 1.63
5-aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-analysis of non-referral populations. Am J Gastroenterol (2012) 1.61
Pathological reassessment of hyperplastic colon polyps in a city-wide pathology practice: implications for polyp surveillance recommendations. Gastrointest Endosc (2012) 1.60
Colonoscopy and its complications across a Canadian regional health authority. Gastrointest Endosc (2009) 1.56
Economic aspects of travelers' diarrhea. J Travel Med (2008) 1.55
The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol (2006) 1.52
Role of biological therapy for inflammatory bowel disease in developing countries. Gut (2011) 1.51
Crohn's disease recurrence in a small bowel transplant. Am J Gastroenterol (2004) 1.49
Expert opinion on vaccination of travelers against Japanese encephalitis. J Travel Med (2009) 1.49
Sexual abuse in irritable bowel syndrome: to ask or not to ask -- that is the question. Can J Gastroenterol (2002) 1.47
A randomized, double-blind, multicenter study of rifaximin compared with placebo and with ciprofloxacin in the treatment of travelers' diarrhea. Am J Trop Med Hyg (2006) 1.46
First-degree relatives of patients with rheumatoid arthritis exhibit high prevalence of joint symptoms. J Rheumatol (2013) 1.44
A population-based study of breastfeeding in inflammatory bowel disease: initiation, duration, and effect on disease in the postpartum period. Am J Gastroenterol (2009) 1.43
Screening for cervical and breast cancer among women with inflammatory bowel disease: a population-based study. Inflamm Bowel Dis (2010) 1.43
The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol (2012) 1.42
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
Brain-gut interactions in inflammatory bowel disease. Gastroenterology (2012) 1.42
Travelers' knowledge, attitudes, and practices on prevention of infectious diseases: results from a pilot study. J Travel Med (2003) 1.36
Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics. Can J Gastroenterol (2013) 1.36
A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am J Epidemiol (2006) 1.33
A population-based study of fatigue and sleep difficulties in inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.32
Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis (2008) 1.30
AMPK agonist downregulates innate and adaptive immune responses in TNBS-induced murine acute and relapsing colitis. Biochem Pharmacol (2010) 1.29
Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol (2006) 1.28
Markers of inflammation in bacterial diarrhea among travelers, with a focus on enteroaggregative Escherichia coli pathogenicity. J Infect Dis (2002) 1.25
Migrants as a major risk group for imported malaria in European countries. J Travel Med (2003) 1.25
Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology (2011) 1.24
Distinct and overlapping genetic loci in Crohn's disease and ulcerative colitis: correlations with pathogenesis. Inflamm Bowel Dis (2010) 1.22
Light visor treatment for jet lag after westward travel across six time zones. Aviat Space Environ Med (2002) 1.21
Nutrition assessment of patients with inflammatory bowel disease. JPEN J Parenter Enteral Nutr (2007) 1.20
Oral p38 mitogen-activated protein kinase inhibition with BIRB 796 for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol (2006) 1.20
Rate of occurrence and pathogenic effect of enteroaggregative Escherichia coli virulence factors in international travelers. J Clin Microbiol (2002) 1.19
Imported infectious disease and purpose of travel, Switzerland. Emerg Infect Dis (2007) 1.18
Deaths caused by malaria in Switzerland 1988-2002. Am J Trop Med Hyg (2006) 1.17
Influenza virus infection in travelers to tropical and subtropical countries. Clin Infect Dis (2005) 1.16
Imported malaria in children in industrialized countries, 1992-2002. Emerg Infect Dis (2009) 1.15
Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Dis (2010) 1.15
The Manitoba IBD Index: evidence for a new and simple indicator of IBD activity. Am J Gastroenterol (2009) 1.15
Are perineal and luminal fistulas associated in Crohn's disease? A population-based study. Clin Gastroenterol Hepatol (2006) 1.15
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Ciprofloxacin or metronidazole for the treatment of perianal fistulas in patients with Crohn's disease: a randomized, double-blind, placebo-controlled pilot study. Inflamm Bowel Dis (2009) 1.14
IBD Around the world: comparing the epidemiology, diagnosis, and treatment: proceedings of the World Digestive Health Day 2010--Inflammatory Bowel Disease Task Force meeting. Inflamm Bowel Dis (2011) 1.14
The evolving epidemiology of inflammatory bowel disease. Curr Opin Gastroenterol (2009) 1.13
Microbial etiology of travelers' diarrhea in Mexico, Guatemala, and India: importance of enterotoxigenic Bacteroides fragilis and Arcobacter species. J Clin Microbiol (2010) 1.12
A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am J Gastroenterol (2006) 1.10
Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum (2012) 1.09
Contributions of IBD5, IL23R, ATG16L1, and NOD2 to Crohn's disease risk in a population-based case-control study: evidence of gene-gene interactions. Inflamm Bowel Dis (2008) 1.09
Gastrointestinal and psychological mediators of health-related quality of life in IBS and IBD: a structural equation modeling analysis. Am J Gastroenterol (2011) 1.09
The incidence of Helicobacter pylori acquisition in children of a Canadian First Nations community and the potential for parent-to-child transmission. Helicobacter (2004) 1.07
Time trends in colon cancer incidence and distribution and lower gastrointestinal endoscopy utilization in Manitoba. Am J Gastroenterol (2008) 1.06
The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am J Gastroenterol (2005) 1.05
Age at acquisition of Helicobacter pylori in a pediatric Canadian First Nations population. Helicobacter (2002) 1.05
A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin Cancer Res (2007) 1.03
Diarrhoea in a large prospective cohort of European travellers to resource-limited destinations. BMC Infect Dis (2010) 1.03
Novel anti-inflammatory action of 5-aminoimidazole-4-carboxamide ribonucleoside with protective effect in dextran sulfate sodium-induced acute and chronic colitis. J Pharmacol Exp Ther (2010) 1.02
Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol (2004) 1.01
Phylogenetic analysis of inflammatory bowel disease associated Escherichia coli and the fimH virulence determinant. Inflamm Bowel Dis (2009) 1.00
Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm Bowel Dis (2010) 1.00
Utilization of health-care resources by patients with IBD in Manitoba: a profile of time since diagnosis. Am J Gastroenterol (2007) 1.00
Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis (2006) 0.99
Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol (2013) 0.99
Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition (2006) 0.99
Association between early childhood otitis media and pediatric inflammatory bowel disease: an exploratory population-based analysis. J Pediatr (2012) 0.98
Physicians' perceptions of risks and practices in venous thromboembolism prophylaxis in inflammatory bowel disease. Dig Dis Sci (2012) 0.98
Health service utilization in IBD: comparison of self-report and administrative data. BMC Health Serv Res (2011) 0.97
Risk factors and management of osteoporosis in inflammatory bowel disease. Curr Opin Gastroenterol (2014) 0.96